Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Calcitonin nebulizer versus colistin-based therapy for ventilator-associated pneumonia
IRCT20251208068246N2Phase 3Recruiting
- Sponsor
- Ahvaz Jundishapur University of Medical Sciences
- Start
- May 2026
- Modality
- Peptides, Small Molecules, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, triple-blind trial of TBRIA and colistin in ventilator-associated pneumonia (VAP) and pneumonia (2 arms), sponsored by Ahvaz Jundishapur University of Medical Sciences. Primary endpoints: Clinical Pulmonary Infection Score and Kidney function. Started May 2026; status: recruiting.
02
Drugs
TBRIAcolistin
03
Conditions
ventilator-associated pneumonia (VAP)pneumonia
Beyond the preview
Go deeper on IRCT20251208068246N2.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20251208068246N2.